BBHC
LXRX icon

Brown Brothers Harriman & Co’s Lexicon Pharmaceuticals LXRX Stock Holding History

Brown Brothers Harriman & Co’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-297
Closed -$4K – 789
2017
Q1 		$4K Hold
297
– – ﹤0.01% 737
2016
Q4 		$4K Hold
297
– – ﹤0.01% 785
2016
Q3 		$5K Hold
297
– – ﹤0.01% 683
2016
Q2 		$4K Buy
+297
New +$4.03K ﹤0.01% 735
2015
Q1 		– Sell
-317
Closed -$2K – 810
2014
Q4 		$2K Buy
+317
New +$2.56K ﹤0.01% 819

Other funds holding LXRX

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UL
Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UIM
USS Investment Management London, United Kingdom $25.6B AUM 30.22% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Brown Brothers Harriman & Co's LXRX Position: Q2 2017 in Review

Brown Brothers Harriman & Co sold out of Lexicon Pharmaceuticals (LXRX) in Q2 2017, closing a stake of 297 shares — an estimated $4K sold.

Brown Brothers Harriman & Co first reported a position in LXRX in Q4 2014 and held it in 5 quarters. The position peaked at $5K in Q3 2016. 135 funds tracked by Wall St. Rank hold LXRX as of Q2 2017.

  • Brown Brothers Harriman & Co reported no remaining Lexicon Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • Brown Brothers Harriman & Co sold 297 Lexicon Pharmaceuticals shares in Q2 2017, an estimated $4K.
  • Brown Brothers Harriman & Co first reported a position in Lexicon Pharmaceuticals in Q4 2014 and held it in 5 quarters.
  • Brown Brothers Harriman & Co's Lexicon Pharmaceuticals position peaked at $5K in Q3 2016.
  • 135 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q2 2017.

Based on Brown Brothers Harriman & Co's 13F filing for Q2 2017, filed 14 Aug 2017.